-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★ Nanjing · Big coffee gathered in May2021 nucleic acid drug development forum announced schedule ★ May Nanjing2021 nucleic acid drug development forum is about to open April 19, 2021 / Yimaike news eMedClub News/--a few days ago, Bristol-Myers Squibb (BMS) announced that the US FDA has approved the PD-1 inhibitor Opdivo (nivolumab) combined with fluoropyrimidine and platinum-based chemotherapy for the treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer (GEJC) or esophageal adenocarcinoma ( EAC) patients, regardless of their PD-L1 expression status.
According to the press release, this approval is based on data from the Phase 3 clinical study CheckMate-649.
The study evaluated Opdivo combined with mFOLFOX6 regimen or CapeOX regimen, and chemotherapy alone (mFOLFOX6 regimen or CapeOX regimen) for the treatment of patients with advanced gastric cancer.
Recommended reading: The King of "Stomach Free" has another victory! O drug has achieved OS/PFS dual superiority, advancing to the first line of gastric cancerMedical Maimen broke the news.
The results of the study showed that among all evaluable patients, the overall survival of the Opdivo combined chemotherapy treatment group was better than that of the chemotherapy alone group.
Those who received Opdivo combined chemotherapy Of the patients, 55% were still alive after one year, compared with 48% of patients receiving chemotherapy alone.
Compared with the chemotherapy alone group, the Opdivo combined chemotherapy treatment group also significantly reduced the risk of disease progression or death.
Yelena Y.
Janjigian, chief investigator of the CheckMate -649 study and director of the Gastrointestinal Oncology Department at Memorial Sloan Kettering Cancer Center, said: "In the CheckMate -649 study, Opdivo combined with chemotherapy can significantly improve metastatic gastric cancer.
GEJC The survival rate of patients with EAC and EAC reduced the risk of death by 20%.
In addition, the one-year survival rate of Opdivo combined with chemotherapy treatment group reached 55%.
Adam Lenkowsky, General Manager of Oncology, Immunology, and Cardiovascular Diseases of Bristol-Myers Squibb, said: "We are committed to providing transformational drugs to patients in need.
Historically, almost all patients diagnosed with metastatic gastroesophageal adenocarcinoma There is no progress in treatment.
In the CheckMate-649 study, Opdivo's first-line treatment for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer (GEJC) or esophageal adenocarcinoma (EAC) showed a higher overall survival rate.
The approval of Opdivo this time will bring new likes to these patients.
"In terms of safety: 44% of patients discontinued Opdivo and/or chemotherapy, and 76% of patients stopped at least one dose due to adverse reactions.
In the
Opdivo combined chemotherapy treatment group, 52% of patients experienced severe adverse reactions, and 2% of patients experienced Fatal adverse reaction.
The
2021 nucleic acid drug development forum will kick off in Nanjing from May 7th to 8th, 2021, to welcome the "new era of super drugs".
According to the press release, this approval is based on data from the Phase 3 clinical study CheckMate-649.
The study evaluated Opdivo combined with mFOLFOX6 regimen or CapeOX regimen, and chemotherapy alone (mFOLFOX6 regimen or CapeOX regimen) for the treatment of patients with advanced gastric cancer.
Recommended reading: The King of "Stomach Free" has another victory! O drug has achieved OS/PFS dual superiority, advancing to the first line of gastric cancerMedical Maimen broke the news.
The results of the study showed that among all evaluable patients, the overall survival of the Opdivo combined chemotherapy treatment group was better than that of the chemotherapy alone group.
Those who received Opdivo combined chemotherapy Of the patients, 55% were still alive after one year, compared with 48% of patients receiving chemotherapy alone.
Compared with the chemotherapy alone group, the Opdivo combined chemotherapy treatment group also significantly reduced the risk of disease progression or death.
Yelena Y.
Janjigian, chief investigator of the CheckMate -649 study and director of the Gastrointestinal Oncology Department at Memorial Sloan Kettering Cancer Center, said: "In the CheckMate -649 study, Opdivo combined with chemotherapy can significantly improve metastatic gastric cancer.
GEJC The survival rate of patients with EAC and EAC reduced the risk of death by 20%.
In addition, the one-year survival rate of Opdivo combined with chemotherapy treatment group reached 55%.
Adam Lenkowsky, General Manager of Oncology, Immunology, and Cardiovascular Diseases of Bristol-Myers Squibb, said: "We are committed to providing transformational drugs to patients in need.
Historically, almost all patients diagnosed with metastatic gastroesophageal adenocarcinoma There is no progress in treatment.
In the CheckMate-649 study, Opdivo's first-line treatment for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer (GEJC) or esophageal adenocarcinoma (EAC) showed a higher overall survival rate.
The approval of Opdivo this time will bring new likes to these patients.
"In terms of safety: 44% of patients discontinued Opdivo and/or chemotherapy, and 76% of patients stopped at least one dose due to adverse reactions.
In the
Opdivo combined chemotherapy treatment group, 52% of patients experienced severe adverse reactions, and 2% of patients experienced Fatal adverse reaction.
The
2021 nucleic acid drug development forum will kick off in Nanjing from May 7th to 8th, 2021, to welcome the "new era of super drugs".
